Modulation of cytotoxic drug activity by dipyridamole.
Schmoll
H J
HJ
Department of Hematology and Oncology, University of Hannover Medical School, FRG.
Harstrick
A
A
Köhne-Wömpner
C H
CH
Schöber
C
C
Wilke
H
H
Poliwoda
H
H
D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000494:pharmacology; D003110:Colonic Neoplasms / Q000188:drug therapy; D003561:Cytarabine / Q000494:pharmacology; D004176:Dipyridamole / Q000008:administration & dosage / Q000494:pharmacology*; D004347:Drug Interactions; D005047:Etoposide / Q000494:pharmacology; D005472:Fluorouracil / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008727:Methotrexate / Q000494:pharmacology
D000970:Antineoplastic Agents; D003561:Cytarabine; D004176:Dipyridamole; D005047:Etoposide; D002945:Cisplatin; D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate